login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Abbott launches MitraClip system in Australia


Friday, 15 Apr 2011 10:58
MitraClip
MitraClip


Abbott announced the launch of its catheter-based MitraClip system in Australia. The MitraClip device, which has received Therapeutic Goods Administration (TGA) approval, offers a new treatment option for patients suffering from mitral regurgitation.


This system includes a catheter-based device that is delivered to the heart through the femoral vein. It is designed to reduce significant mitral regurgitation by clipping together the leaflets of the mitral valve. Mitral regurgitation has traditionally been managed with medications, which can relieve symptoms but do not address the underlying cause of the condition, or open-heart surgery. According to Bach et al, many people who suffer from mitral regurgitation are not treated surgically because they are not referred to surgery, are not sick enough, or are too frail for an invasive procedure.

 

“The availability of the MitraClip system provides physicians with a safe, minimally invasive treatment for mitral regurgitation that may provide new hope for many people for whom surgery is not an option,” said Eric Yamen, Sir Charles Gairdner Hospital, Perth, Australia. “This therapy has the potential to improve the quality of life for many sick patients, enabling them to have a more active lifestyle.”

 

The first patients were successfully treated in Australia by interventional cardiologist, Eric Yamen; cardiothoracic surgeon, Jurgen Passage and echocardiologist, Christopher Finn; all from Sir Charles Gairdner Hospital, Perth, Australia.

 

Robert Hance, senior vice president, Vascular, Abbott, commented “Nearly 3,000 patients around the world have benefited from MitraClip treatment, and we are pleased that it is now commercially available in Australia.”

 

New clinical study to gather additional clinical and health-economic data

 

Abbott also announced the initiation of a new clinical study of the MitraClip device that will enroll up to 150 patients at up to 15 sites in Australia and New Zealand. The primary objective of the single-arm, prospective trial is to gather real-world clinical and health-economic outcome data to evaluate the long-term safety, efficacy and economic value of the MitraClip system. Patients in the study will be evaluated at discharge and after 30 days and six, 12 and 24 months following the procedure.

 

Patients will be selected for inclusion in the study by a multidisciplinary team involving specialists in interventional cardiology, cardiac surgery and echocardiology.

 

David Muller, director of the Cardiac Catheterization Laboratories, St Vincent’s Hospital, Sydney, Australia, and Jurgen Passage, cardiothoracic surgeon, Sir Charles Gairdner Hospital, Perth, Australia, will serve as the principal investigators of the study.

 

About the MitraClip technology and procedure

 

The catheter-based MitraClip device is delivered to the heart through the femoral vein. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. After treatment, patients are usually home within two to three days and have been observed to recover quickly. The safety and efficacy of the MitraClip system was evaluated in EVEREST II, the first randomised clinical trial to compare a catheter-based mitral valve device to mitral valve surgery.

 

The MitraClip system was CE marked in March 2008 and is commercially available in Europe, Turkey, Israel and Australia. The first-in-man clinical trial of the MitraClip system was conducted in the United States, where it is an investigational device currently under review for approval by the FDA.

 

 

 




Add New Comment

Related Items


Most popular


Tuesday, 12 Aug 2014
Toshiba has announced that it will feature SURESubtraction Coronary at The European Society of Cardiology (ESC) congress (30 August–3 September, Barcelona, Spain). Toshiba Introduces SURESubtraction Coronary at ESC 2014

Friday, 04 Jul 2014
A new study suggests that transradial access in patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention is associated with reduced bleeding ... Transradial access predicts survival in NSTEMI patients

Friday, 22 Aug 2014
Royal Philips has announced that it has received 510(k) clearance from the US Food and Drug Administration to market its precision planning application for transcatheter aortic-valve implantation (TAV... FDA 510(k) clearance for TAVI precision treatment planning application

Features


Transitioning from transfemoral to transradial: Why the transradial approach is here to stay
Thursday, 21 Aug 2014
William H Crowder believes that, despite some US interventional cardiologists’ reluctance to use the approach, the transradial approach will become standard of care for coronary catheterisation ... Transitioning from transfemoral to transradial: Why the transradial approach is here to stay

The role of rotational atherectomy in contemporary PCI practice
Thursday, 07 Aug 2014
James Cockburn, David Hildick-Smith, and Adam de Belder describe their recent study (published in the International Journal of Cardiology), which found that patients who underwent rotational ... The role of rotational atherectomy in contemporary PCI practice

Profiles


David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Ashok Seth
Wednesday, 12 Feb 2014
Ashok Seth is the immediate past president of Cardiological Society of India and is the principal ... Ashok Seth

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions